## **Listing of Claims:**

2

1	1-31. (Canceled)
1	32. (Currently amended) A <u>probe nucleic acid</u> eompound having the formula
	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
2	X 0 Y
3	wherein,
4	NA is a nucleic acid chain comprising nucleic acid monomers selected from the
5	group consisting of natural nucleic acids, modified nucleic acids and
6	combinations thereof;
7	R <sup>1</sup> , R <sup>2</sup> , R <sup>3</sup> and R <sup>4</sup> are linker moieties independently selected from the group
8	consisting of substituted or unsubstituted alkyl and substituted or
9	unsubstituted heteroalky1;
10	Nu <sup>1</sup> and Nu <sup>2</sup> are members independently selected from the group consisting of
11	nucleotide residues and nucleoside residues;
12	R is a molecular energy transfer donor;
13	Q is a molecular energy acceptor; and
14	X and Y are the same or different and are non-nucleic acid stabilizing moieties
15	that interact to bring R and Q into operative proximity, thereby enabling
16	transfer of energy from R to Q, wherein said probe nucleic acid sequence
17	is not hybridized to a target nucleic acid.
1	33. (Previously Presented) The compound according to claim 32, wherein
2	said molecular energy transfer donor is a fluorophore.
1	34. (Previously Presented) The compound according to claim 32, wherein

said molecular energy acceptor is a fluorescence quencher.

1	35. (Previously Presented) The compound according to claim 32, wherein X
2	and Y are both hydrophobic moieties.
1	36. (Previously Presented) The compound according to claim 35, wherein X
2	and Y are members independently selected from the group consisting of saturated hydrocarbons,
3	unsaturated hydrocarbons, steroids, fatty acids, fatty alcohols and hydrophobic peptides.
J	unsaturated hydrocarbonis, sterotes, ratty across and my arepticese pepsiess.
1	37. (Previously Presented) The compound according to claim 32, wherein
2	natural nucleic acids are members selected from the group consisting of deoxyribonucleotides,
3	ribonucleotides and combinations thereof.
1	38. (Previously Presented) The compound according to claim 32, wherein
1	
2	said modified nucleic acids are peptide nucleic acids.
1	39. (Previously Presented) The compound according to claim 32, wherein
2	said nucleic acid monomers are joined by linkages that are members independently selected from
3	the group consisting of phosphodiesters and modified phosphodiesters.
1	40 (Durai anala Durantad). The commound eccording to claim 20 wherein
1	40. (Previously Presented) The compound according to claim 39, wherein
2	said modified phosphodiesters are members selected from the group consisting of
3	phosphorothioates and phosphoramidates.
1	41. (Previously Presented) The compound according to claim 32, wherein
2	said nucleic acid chain further comprises a hybridization enhancing moiety.
1	42. (Previously Presented) The compound according to claim 41, wherein
2	said hybridization enhancing moiety is a member selected from the group consisting of
3	intercalating agents, minor groove binders and modified exocyclic bases.
1	43. (Cancel)
I	45. (Cancer)

(Previously Presented) The compound according to claim 32, wherein 44. 1 said compound is immobilized on a solid surface. 2 (Previously Presented) A method for amplifying a polynucleotide, 1 45. wherein a compound according to claim 32 is a primer in said method, said method comprising: 2 (a) hybridizing said primer to said polynucleotide; and 3 (b) amplifying said polynucleotide. 4 (Previously Presented) The method according to claim 45, wherein said 46. 1 2 amplifying is a member selected from the group consisting of polymerase chain reaction (PCR), nucleic acid sequence based amplification (NASBA), strand displacement amplification (SDA) 3 4 and combinations thereof. 47. (Previously Presented) A method for detecting or quantitating a nucleic 1 acid, wherein the compound according to claim 32 is used as a probe, said method comprising: 2 (a) hybridizing said compound to said nucleic acid; and 3 (b) detecting a change in fluorescence of said compound, thereby detecting or 4 quantitating said nucleic acid. 5 48. (Previously Presented) The method according to claim 47, wherein said 1 method comprises a member selected from the group consisting of 5'-nuclease assay, rolling 2 3 circle amplification and combinations thereof. 49. (Previously Presented) A kit for quantitating nucleic acid, said kit 1 2 comprising a compound according to claim 32. 50. (Previously Presented) A compound having the formula: 1 2

 $D-R^{1}-Nu^{1}-R^{2}-O-P-O-NA-O-P-O-R^{3}-Nu^{2}-R^{4}-Q$  CHOI

3

4	wherein,
5	CHOL is a cholesterol derivative;
6	R <sup>1</sup> , R <sup>2</sup> , R <sup>3</sup> and R <sup>4</sup> are linker moieties independently selected from the group
7	consisting of substituted or unsubstituted alkyl and substituted or
8	unsubstituted heteroalky1;
9	Nu <sup>1</sup> and Nu <sup>2</sup> are members independently selected from the group consisting of
10	nucleotide residues and nucleoside residues;
11	NA is a nucleic acid sequence;
12	D is a donor of light energy; and
13	Q is a quencher of light energy,
14	wherein the CHOL moieties interact to bring D and Q into operative proximity,
15	thereby enabling transfer of energy from D to Q.
1	51. (Previously Presented) The compound according to claim 50, wherein
2	R <sup>2</sup> -CHOL and R <sup>3</sup> -CHOL are independently selected and have structures according to the
3	formula:
	—-Ŗ <sup>11</sup> —
	PEG
	<b>y</b> 3
4	сног
5	wherein,
6	R <sup>11</sup> is a member selected from the group consisting of substituted or unsubstituted
7	alkyl and substituted or unsubstituted heteroalkyl;
8	PEG is polyethylene glycol;
9	Y <sup>3</sup> is an organic functional group adjoining said PEG to said CHOL.
1	52. (Previously Presented) The compound according to claim 51, wherein
2	said PEG has from about 2 to about 20 ethylene glycol subunits.

- 1 53. (Previously Presented) The compound according to claim 51 in which R<sup>11</sup>
  2 is substituted or unsubstituted alkyl.
- 1 54. (Previously Presented) The compound according to claim 53, wherein R<sup>11</sup> 2 is C<sub>1</sub>-C<sub>6</sub> substituted or unsubstituted alkyl.
- 1 55. (Previously Presented) The compound according to claim 51, wherein 2 Y<sup>3</sup>-CHOL has the structure:

1 56. (Previously Presented) The compound according to claim 50, wherein 2 Nu<sup>1</sup> and Nu<sup>2</sup> are nucleotides having an exocyclic amine group to which -R<sup>1</sup>-D and -R<sup>4</sup>Q are attached, respectively.

57. (Previously Presented) A compound having the formula:

3 wherein,

3

1

2

5

6

4 NA is a nucleic acid sequence;

Nu<sup>1</sup> and Nu<sup>2</sup> are members independently selected from the group consisting of nucleotide residues and nucleoside residues;

7	Y <sup>1</sup> and Y <sup>2</sup> are linking groups independently selected from the group consisting of
8	substituted or unsubstituted alkyl and substituted or unsubstituted
9	heteroalkyl;
10	R <sup>5</sup> and R <sup>6</sup> are linking groups independently selected from the group consisting of
11	substituted or unsubstituted alkyl and substituted or unsubstituted
12	heteroalkyl;
13	D is a donor of light energy; and
14	Q is a quencher of light energy,
15	wherein each CHOL interacts with the other CHOL to bring D and Q into operative
16	proximity, thereby enabling transfer of energy from D to Q.
1	58. (Previously Presented) The compound according to claim 57, wherein Y <sup>1</sup>
2	and Y <sup>2</sup> are members independently selected from substituted or unsubstituted heteroalkyl.
1	59. (Previously Presented) The compound according to claim 58, wherein Y <sup>1</sup>
2	and Y <sup>2</sup> are polyethylene glycol.
ì	60. (Previously Presented) The compound according to claim 59, wherein
2	said polyethylene glycol has from about 2 to about 20 ethylene glycol subunits.
1	61. (Previously Presented) The compound according to claim 57, wherein
2	Y <sup>1</sup> -CHOL and Y <sup>2</sup> -CHOL have the structure:

62. (Cancel)

3

1